Casimir Further Differentiates Emmes’ Industry-Leading Rare Disease Research Capabilities Rockville, MD, March 10, 2022 – Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Casimir, a U.S.-based CRO. Casimir has experience in more than 20 rare diseases and has worked with regulators, sponsors and patients to develop outcome measures that capture the nuances of disease progression and treatment benefit. Emmes Chief Executive Officer Dr. Christine Dingivan said, “This is the fourth acquisition for Emmes in just over a year, as we continue to add new biopharma
The post Emmes Acquires Casimir, Its Fourth Major Acquisition appeared first on Pharma Mirror Magazine.
